A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

NCT07639021 · Recruiting

Last updated 2026-07-12

This study is testing different methods of increasing the dose of the medication NNC0662-0419 in adults with obesity to observe any side effects, particularly stomach or digestive issues.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 230 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-06 · est. completion 2027-07

Where 25 sites · Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT07639021 ↗

Description as written by the study sponsor.

The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.

Treatments tested

NNC0662-0419 Drug

NNC0662-0419 will be administered subcutaneously.
Semaglutide Drug

Semaglutide will be administered subcutaneously.
NNC0662-0419 Placebo Drug

Placebo matched to NNC0662-0419 will be administered subcutaneously.
Semaglutide placebo Drug

Placebo matched to semaglutide will be administered subcutaneously.

Main thing measured	Number of gastrointestinal adverse events
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07639021 ↗